Valuation models
price $165.00 · as of Nov 2, 2026
PEG—340.7152% undervaluedEV/EBITDA · peersused—147.3012% overvaluedEV/Revenue · peers381.84 – 1,862.44409.1260% undervaluedWall St. consensus target—315.0048% belowCost of capital (WACC)—7.45%—
EV/EBITDA · peers leads because DCF · Perpetuity growth · 5y could not run on the filed statements; P/E · peers returned no positive value. How the headline model is chosen.
Model value · EV/EBITDA · peers
147.30
Alnylam Pharmaceuticals closed at $165.00 — overvalued by 12% vs model.
147.30the model's range147.30
EV/EBITDA · peers leads because DCF · Perpetuity growth · 5y could not run on the filed statements; P/E · peers returned no positive value. From its peers' median EV/EBITDA.
Other models
340.71 – 409.12
Wall St. target
315.00 48% below
Above model, 1y
24 of 30 days
How it is valued
Valued asHigh growth
High revenue growth (~43% recent)Moderate margins (8% net margin)Highly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.